Abstract: This disclosure provides for compositions and methods for treating incipient or moderate pulmonary fibrosis and idiopathic pulmonary fibrosis (collectively pulmonary fibrosis or “PF”) in patients in need thereof. Provided is a dry powder composition comprising an effective amount of a) pirfenidone; and b) nintedanib or a pharmaceutically acceptable salt thereof, wherein the composition is suitable for direct pulmonary delivery. Also contemplated are compositions for direct pulmonary delivery comprising 1 to 5 active pharmaceutical ingredients.